Comparative Pharmacology
Head-to-head clinical analysis: ISOETHARINE HYDROCHLORIDE versus ISOETHARINE HYDROCHLORIDE S F.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOETHARINE HYDROCHLORIDE versus ISOETHARINE HYDROCHLORIDE S F.
ISOETHARINE HYDROCHLORIDE vs ISOETHARINE HYDROCHLORIDE S/F
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ISOETHARINE HYDROCHLORIDE is a beta-2 adrenergic receptor agonist that stimulates adenylate cyclase, increasing cyclic AMP (cAMP) in bronchial smooth muscle, leading to bronchodilation. It also has beta-1 activity at higher doses, causing cardiac stimulation.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
Inhalation via nebulizer: 0.5 mL (2.5 mg) of 0.5% solution diluted in 2-3 mL normal saline, administered over 10-20 minutes, every 4-6 hours as needed.
Inhalation: 1-2 inhalations of a 340 mcg/metered dose every 4 hours as needed. Nebulization: 500 mcg (0.5 mL of a 0.1% solution) every 4 hours as needed.
None Documented
None Documented
1.6 to 2.7 hours in adults; may be prolonged in patients with hepatic or renal impairment.
2-4 hours; clinical context: short half-life supports continuous or repeated dosing for acute bronchospasm.
Primarily renal excretion of unchanged drug and metabolites; approximately 60-80% of a dose is excreted in urine within 24 hours, with the remainder excreted in feces via biliary elimination.
Primarily renal excretion of unchanged drug and metabolites; 60-70% excreted in urine as unchanged drug and sulfate conjugates, with less than 10% eliminated in feces via biliary excretion.
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist